Sign in
Taking people in South KoreaNo phase

Protecting the Kidneys During Contrast Imaging in People With Acute Heart Failure

Compares furosemide with saline fluids to protect kidneys during contrast scans in heart failure.

Key facts

Who runs it
Jin Joo Park
Where
Seongnam-si, South KoreaSee the site
Trial code
Registry title
Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
Status
Recruiting
People taking part
190 people, planned
Started
1 Jul 2026
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Furosemide
  • 0.9 % Normal Saline
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital with acute heart failure and congestion who have mildly to moderately reduced kidney function and need a contrast CT scan.

Age
20 years or older
Sex
All sexes can join
Disease stage
Acute heart failure with clear signs of fluid congestion, and kidney function (eGFR) of 30-75 mL/min/1.73 m²
Biomarker or test result
eGFR of 30-75 mL/min/1.73 m²

Main reasons for not taking part

  • Needs vasopressor medicine
  • Needs dialysis or other kidney replacement treatment
  • Allergy to furosemide
  • Ongoing acute coronary syndrome
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults aged 20 years or older
  • Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion
  • Planned contrast-enhanced computed tomography during the index hospitalization
  • Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m²

Who cannot take part

  • Requirement for vasopressor therapy
  • Requirement for renal replacement therapy (dialysis)
  • Known allergy or hypersensitivity to furosemide
  • Ongoing acute coronary syndrome
  • Any condition deemed by the investigator to make participation in the study inappropriate
  • Hyperkalemia (serum potassium >5.5 mmol/L)
  • Uncorrected volume depletion or hyponatremia (serum sodium <130 mmol/L)
  • Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test

Where in South Korea

  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Minjae Yoon, MDTaking people

About the trial

What the trial wants to find out

The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.

The 2 groups in the trial

  • Standard Intravenous Saline HydrationExisting treatment, for comparison

    Participants receive standard intravenous hydration with 0.9% normal saline (1ml/kg) before and after contrast-enhanced computed tomography as a conventional strategy for the prevention of contrast-induced acute kidney injury.

    Treatment: 0.9 % Normal Saline

  • Furosemide-Based Decongestion StrategyTreatment being tested

    Participants receive intravenous furosemide to achieve sufficient diuresis (target ≥1,000 mL) as a decongestion-based strategy for renal protection before contrast-enhanced computed tomography.

    Treatment: Furosemide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)
Plain-language title
Protecting the Kidneys During Contrast Imaging in People With Acute Heart FailureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
16 July 2026